Ischemic Heart Disease
Conditions
Keywords
Absorb GT1 BVS, BVS, Bioabsorbable, Myocardial ischemia, Stent thrombosis, Stents
Brief summary
The ABSORB Post-Approval Clinical Study is a prospective, open-label, multi-center, single-arm, non-randomized trial to evaluate the safety of the use of ABSORB in a real-world setting following commercial physician training'and to observe the effectiveness of commercial physician training on appropriate vessel sizing.
Detailed description
After approval of commercial use of Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System in over 75 countries as of December 31, 2015, Abbott Vascular has developed a post-approval commitment plan that includes the initiation of the ABSORB Post-Approval Clinical Study, a single-arm trial that will include approximately 2000 subjects at approximately 265 sites in the US and Canada. The objectives of ABSORB PostApproval Study are the following: * Evaluate the safety of the use of Absorb in a real world setting following commercial physician training. * Observe the effectiveness of commercial physician training on appropriate vessel sizing in the use of Absorb in a real world setting. The study design allows evaluating low frequency events, effectiveness of commercial physician training and education for very small vessels (\< 2.25 mm as assessed by quantitative coronary angiography \[QCA\]), and confirmation of generalizability of the treatment with Absorb to real-world practice. The estimated follow-up of safety and effectiveness will be 3 years. Angiographic Subgroup: Approximately the first 500 consecutive subjects implanted by operators inexperienced in the usage of Absorb GT1 BVS to receive baseline assessment of reference vessel diameter (RVD) by the angiographic core laboratory. An inexperienced operator is defined as having performed two or fewer Absorb implants prior to commercial approval. The purpose of the angiographic subgroup is to evaluate the effectiveness of training in the selection of appropriately sized coronary arteries for GT1 BVS implantation. Study staff will be notified after the procedure if the subject is in the angiographic subgroup, and instructed to send pre-procedure angiogram and supporting materials to core laboratory for assessment.
Interventions
DEVICEAbsorb BVS
Commercially approved Absorb GT1 BVS, herein referred to as Absorb. * Scaffold diameters: 2.5, 3.0, and 3.5 mm * Scaffold lengths: 8, 12, 18, 23 and 28 mm Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Sponsors
Abbott Medical Devices
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject agrees and signs the Institutional Review Board (IRB) approved informed consent form * The subject receives an Absorb
Exclusion criteria
* Subject is a member of a vulnerable population. Vulnerable population: Defined as subject whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples of populations which may contain vulnerable subjects include: Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of cardiac death, myocardial infarction (CD/MI) | 1 year | Myocardial infarction will be assessed per the Universal MI definition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The annual rate of definite/probable scaffold thrombosis | At 1 year post-index procedure | ST is assessed per the Academic Research Consortium (ARC) definite/probable definition. |
| Percentage of very small vessels (per-lesion basis) | Pre-procedure (on day 0) | This is the commercial Training Assessment Endpoint (Angiographic Subgroup only). Pre-procedure reference vessel diameter (RVD) \< 2.25 mm as assessed by core laboratory using quantitative coronary angiography (QCA). |
| Death (Cardiac, Non-Cardiac) | ≤ 7 days post index procedure (In-hospital ) | Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. |
| All Myocardial Infarction (All MI) | ≤ 7 days post index procedure (In-hospital ) | — |
| Target Lesion Revascularization (TLR) | ≤ 7 days post index procedure (In-hospital ) | TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. |
| Ischemia Driven TLR (ID-TLR) | ≤ 7 days post index procedure (In-hospital ) | TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. |
| Target Vessel Revascularization (TVR) | ≤ 7 days post index procedure (In-hospital ) | TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. |
| All coronary revascularization | ≤ 7 days post index procedure (In-hospital ) | — |
| Definite/probable scaffold thrombosis (ST) | 1 year | ST is assessed per the Academic Research Consortium (ARC) definite/probable definition. |
| Death/All Myocardial Infarction (MI) | ≤ 7 days post index procedure (In-hospital ) | All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. |
| Cardiac Death/All Myocardial Infarction (MI) | ≤ 7 days post index procedure (In-hospital ) | Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. |
| Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [Target vessel failure;TVF] | ≤ 7 days post index procedure (In-hospital ) | — |
| Cardiac Death/All Myocardial Infarction (MI)/Target vessel revascularization (TVR) [TVF] | 30 days | — |
| Cardiac Death/TV MI/ID-TLR (Target lesion failure;TLF) | ≤ 7 days post index procedure (In-hospital ) | — |
| Cardiac Death/TV MI/ID-TLR (TLF) | 30 days | — |
| Death/All Myocardial Infarction (MI)/All revascularization | ≤ 7 days post index procedure (In-hospital ) | — |
| Scaffold thrombosis (per ARC definition) | Acute (0 - 24 hours post stent implantation) (Definite and Probable) | Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab. Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: \>24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: \>1 year post stent implantation |
Countries
United States
Outcome results
None listed